MCID: DCT002
MIFTS: 59

Ductal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 29 15
Noninfiltrating Intraductal Carcinoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060074
UMLS 71 C0007124

Summaries for Ductal Carcinoma in Situ

Disease Ontology : 12 A breast carcinoma in situ that is characterized by being non-invasive, not having spread outside of the duct into the surrounding breast tissue, has material basis in abnormally proliferating cells, derives from epithelial cells.

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and squamous cell papilloma. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Sufentanil and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 523)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.9 TP53 PGR ESR1 ERBB2
2 squamous cell papilloma 31.8 TP53 KRT14 CDKN2A
3 gynecomastia 31.6 PGR ESR1 ERBB2 CYP19A1
4 mammographic density 31.6 PGR ESR1 CYP19A1
5 breast fibroadenoma 31.5 TP53 PGR KRT14 ESR1 ERBB2 CYP19A1
6 mammary paget's disease 31.4 PGR MUC1 KRT14 ESR1 ERBB2 EGFR
7 in situ carcinoma 31.4 TP53 PGR MUC1 MIR17 KRT5 KRT14
8 intraductal papilloma 31.4 PGR KRT5 KRT14 ESR1 ERBB2 CD44
9 lobular neoplasia 31.3 TP53 PGR MUC1 KRT5 ESR1 ERBB2
10 tubular adenocarcinoma 31.2 PGR MUC1 ESR1 ERBB2 EGFR CDH1
11 papillary carcinoma 31.2 PGR MUC1 ESR1 ERBB2 CDH1 CD44
12 papilloma 31.1 TP53 PTGS2 KRT5 KRT14 ESR1 EGFR
13 breast ductal carcinoma 31.1 TP53 PGR MUC1 MIR17 KRT5 KRT14
14 female breast cancer 31.0 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
15 microglandular adenosis 30.9 TP53 PGR ESR1 ERBB2 EGFR CDH1
16 estrogen excess 30.9 PGR ESR1 CYP19A1
17 vaginal discharge 30.9 PGR ESR1 CYP19A1
18 adenoma 30.9 TP53 PTGS2 MUC1 CDKN2A CDH1 CCND1
19 bilateral breast cancer 30.9 PGR ESR1 ERBB2 CDKN2A CDH1 BRCA2
20 breast disease 30.8 TP53 PGR MIR17 KRT5 ESR1 ERBB2
21 papillary serous adenocarcinoma 30.8 TP53 PGR BRCA2 BRCA1
22 exanthem 30.8 ERBB2 EGFR AKT1
23 pleomorphic carcinoma 30.8 TP53 PGR KRT14 EGFR
24 cribriform carcinoma 30.8 PGR KRT5 ESR1 ERBB2
25 hidradenoma 30.8 MUC1 KRT5 AKT1
26 spindle cell carcinoma 30.7 PGR MUC1 KRT5 KRT14 ESR1 CDH1
27 rare breast tumor 30.7 TP53 ESR1 ERBB2 BRCA2 BRCA1
28 adenosquamous carcinoma 30.6 TP53 PGR MUC1 KRT5 EGFR
29 pleomorphic adenoma 30.6 TP53 MUC1 KRT14 ERBB2 CDKN2A
30 b-cell lymphoma 30.6 TP53 MIR17 CDKN2A CD44 CCND1
31 breast carcinoma in situ 30.6 TP53 PGR KRT5 KRT14 ESR1 ERBB2
32 insulin-like growth factor i 30.5 ESR1 EGF AKT1
33 serous cystadenocarcinoma 30.5 TP53 PGR ERBB2 CDKN2A BRCA2 BRCA1
34 apocrine adenocarcinoma 30.5 TP53 PGR MUC1 KRT5 ESR1 ERBB2
35 hypertrophy of breast 30.4 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
36 skin carcinoma 30.4 TP53 PTGS2 EGFR CDKN2A CDH1 CCND1
37 wilms tumor 1 30.3 TP53 PGR ESR1 ERBB2 EGFR CDH1
38 cataract 30.2 TP53 PTGS2 ESR1 EGFR EGF CDH1
39 breast cancer 30.2 TP53 PTGS2 PGR MUC1 MIR17 KRT5
40 adenocarcinoma 30.1 TP53 PTGS2 MUC1 ERBB2 EGFR EGF
41 lymphoma 30.1 TP53 MUC1 EGFR CDKN2A CDH1 CD44
42 sporadic breast cancer 30.0 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
43 squamous cell carcinoma 29.8 TP53 PTGS2 MUC1 KRT14 ERBB2 EGFR
44 endometrial cancer 29.7 TP53 PGR MUC1 ESR1 ERBB2 EGFR
45 adenoid cystic carcinoma 29.5 TP53 PGR MUC1 KRT5 KRT14 ERBB2
46 hepatocellular carcinoma 29.3 TP53 PTGS2 MIR17 ESR1 ERBB2 EGFR
47 lung cancer 28.8 TP53 PTGS2 MUC1 MIR17 KRT5 ESR1
48 prostate cancer 28.6 TP53 PTGS2 PGR MUC1 MIR17 KRT5
49 breast apocrine carcinoma in situ 11.4
50 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.91 EGFR
2 Decreased viability GR00055-A-2 9.91 EGFR
3 Decreased viability GR00221-A-1 9.91 AKT1 CDH1 CDKN2A EGFR ESR1
4 Decreased viability GR00221-A-2 9.91 AKT1 ESR1
5 Decreased viability GR00221-A-3 9.91 AKT1 CDKN2A ERBB2
6 Decreased viability GR00221-A-4 9.91 AKT1 CDKN2A EGFR ESR1 ERBB2
7 Decreased viability GR00249-S 9.91 AKT1
8 Decreased viability GR00301-A 9.91 CDH1
9 Decreased viability GR00386-A-1 9.91 ESR1
10 Decreased viability GR00402-S-2 9.91 CDH1 ESR1

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
2 integument MP:0010771 10.5 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
3 cellular MP:0005384 10.49 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
4 endocrine/exocrine gland MP:0005379 10.49 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
5 digestive/alimentary MP:0005381 10.48 BRCA1 BRCA2 CCND1 CD44 CDH1 CDKN2A
6 homeostasis/metabolism MP:0005376 10.47 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
7 behavior/neurological MP:0005386 10.44 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
8 cardiovascular system MP:0005385 10.43 AKT1 BRCA1 CCND1 CD44 CDH1 CDKN2A
9 immune system MP:0005387 10.43 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
10 hematopoietic system MP:0005397 10.42 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
11 mortality/aging MP:0010768 10.41 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
12 embryo MP:0005380 10.34 AKT1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
13 neoplasm MP:0002006 10.32 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
14 normal MP:0002873 10.25 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
15 muscle MP:0005369 10.24 AKT1 BRCA1 CD44 CDKN2A CYP19A1 EGFR
16 adipose tissue MP:0005375 10.23 AKT1 BRCA1 CYP19A1 EGFR ESR1 KRT14
17 nervous system MP:0003631 10.23 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
18 limbs/digits/tail MP:0005371 10.19 BRCA1 BRCA2 CD44 EGFR ERBB2 ESR1
19 reproductive system MP:0005389 10.16 AKT1 BRCA1 BRCA2 CCND1 CD44 CDH1
20 liver/biliary system MP:0005370 10.13 AKT1 CD44 CDKN2A CYP19A1 EGFR ESR1
21 no phenotypic analysis MP:0003012 9.98 CDH1 CDKN2A EGFR ESR1 PGR PTGS2
22 renal/urinary system MP:0005367 9.92 BRCA1 CD44 CLDN7 CYP19A1 EGFR ESR1
23 pigmentation MP:0001186 9.91 BRCA1 CD44 CDKN2A CYP19A1 EGFR KRT14
24 respiratory system MP:0005388 9.9 AKT1 BRCA1 CCND1 CD44 CDKN2A EGFR
25 skeleton MP:0005390 9.77 AKT1 BRCA1 BRCA2 CCND1 CD44 CDKN2A
26 vision/eye MP:0005391 9.28 CCND1 CD44 CDKN2A CYP19A1 EGF EGFR

Drugs & Therapeutics for Ductal Carcinoma in Situ

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
2
Ondansetron Approved Phase 4 99614-02-5 4595
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4 Anesthetics Phase 4
5 Anesthetics, Local Phase 4
6 Analgesics Phase 4
7 Narcotics Phase 4
8 Anesthetics, General Phase 4
9 Analgesics, Opioid Phase 4
10 Anesthetics, Intravenous Phase 4
11
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
12
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
13
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
14
Sodium citrate Approved, Investigational Phase 3 68-04-2
15
Tamoxifen Approved Phase 3 10540-29-1 2733526
16
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
17
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
20
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
21
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
22
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
23
Daunorubicin Approved Phase 3 20830-81-3 30323
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25 Anti-Allergic Agents Phase 3
26 Contraceptive Agents Phase 3
27 Contraceptives, Oral Phase 3
28 Contraceptive Agents, Male Phase 3
29
Medroxyprogesterone Phase 3 520-85-4 10631
30 Hormone Antagonists Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 Estrogen Antagonists Phase 3
33 Aromatase Inhibitors Phase 3
34 Estrogens Phase 3
35 Estrogen Receptor Antagonists Phase 3
36 Citrate Phase 3
37 Estrogen Receptor Modulators Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Immunoglobulins Phase 3
40 Antibodies Phase 3
41 Antibodies, Monoclonal Phase 3
42 Immunoglobulins, Intravenous Phase 3
43 Immunologic Factors Phase 3
44 Antirheumatic Agents Phase 3
45
Liposomal doxorubicin Phase 3 31703
46 Anti-Bacterial Agents Phase 3
47 Antibiotics, Antitubercular Phase 3
48 Tubulin Modulators Phase 3
49 Antimitotic Agents Phase 3
50 Albumin-Bound Paclitaxel Phase 3

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. Recruiting NCT04248179 Phase 4 Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
2 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
3 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
4 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
5 Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy Completed NCT00438659 Phase 3 mometasone furoate
6 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
7 Genetic Counseling for Newly Diagnosed Breast Cancer Patients Completed NCT00262899 Phase 3
8 Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group) Completed NCT02295033 Phase 3
9 A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
10 A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen Completed NCT00003140 Phase 3 letrozole
11 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
12 Prospective Randomized Study of Accelerated Radiation Therapy (PRART) Recruiting NCT04175210 Phase 3
13 Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Randomized, Multicentre, Non-inferiority Trial, Between Standard Therapy Approach Versus Active Surveillance Recruiting NCT02492607 Phase 3
14 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
15 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
16 International Breast Cancer Intervention Study II (IBIS-II) (DCIS) Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
17 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
18 A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS Active, not recruiting NCT00907868 Phase 3
19 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
20 International Breast Cancer Intervention Study Active, not recruiting NCT00078832 Phase 3 anastrozole;placebo
21 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
22 International Breast Cancer Intervention Study: A Multicentre Trial of Tamoxifen to Prevent Breast Cancer Active, not recruiting NCT00002644 Phase 3 Tamoxifen Citrate 20Mg Tab
23 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer Active, not recruiting NCT01275677 Phase 3 Cyclophosphamide;Docetaxel;Doxorubicin;Doxorubicin Hydrochloride;Paclitaxel
24 Evaluation of the LightPath® Imaging System and the PET Tracer 68Ga-RM2 in Wide Local Excision (WLE) for Breast Cancer Not yet recruiting NCT03731026 Phase 3 68Ga-RM2
25 A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women Withdrawn NCT00324714 Phase 3 risedronate sodium
26 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
27 A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
28 Phase II Study - Dose Optimization PDR/HDR Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
29 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
30 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
31 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
32 A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole Completed NCT00354640 Phase 2 anastrozole;simvastatin
33 A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer Completed NCT00334542 Phase 2 simvastatin
34 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
35 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
36 MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) Completed NCT00586326 Phase 2
37 Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial Completed NCT01023477 Phase 1, Phase 2 Chloroquine Standard Dose (500mg/week);Chloroquine Low Dose (250mg/week)
38 Intraoperative Radiation Therapy to the Tumor Bed for Boost Treatment After Lumpectomy Prior to Whole Breast Radiation in Breast Conservation Candidates Completed NCT00054301 Phase 2
39 Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy Completed NCT00244959 Phase 2 anastrozole
40 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
41 Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery Completed NCT00003099 Phase 2 Fenretinide;Tamoxifen Citrate
42 Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer Completed NCT02137252 Phase 2 Naltrexone;Sugar Pill
43 A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Completed NCT01194440 Phase 2 letrozole;zoledronic acid
44 Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer Completed NCT00107510 Phase 2 carboplatin;docetaxel
45 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
46 Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population Completed NCT00764322 Phase 2 tamoxifen citrate
47 A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer Completed NCT00073073 Phase 2 Exemestane
48 Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women Completed NCT00256217 Phase 2 Anastrozole
49 A Phase IB Trial of Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS Recruiting NCT03793829 Phase 1, Phase 2
50 Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery Recruiting NCT03535506 Phase 2 Palbociclib

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 29

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

40
Breast, Lymph Node, Testes, Skin, Bone, Endothelial, Salivary Gland

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 6680)
# Title Authors PMID Year
1
Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer. 61
32447596 2020
2
Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants. 61
31974710 2020
3
Predictors for upstaging of ductal carcinoma in situ (DCIS) to invasive carcinoma in non-mass-type DCIS. 61
32454975 2020
4
Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. 61
32302762 2020
5
Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good? 61
32430678 2020
6
Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition. 61
32134153 2020
7
The impact of ductal carcinoma in situ on health services utilization. 61
32385793 2020
8
Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision. 61
32144463 2020
9
The 2018 assisi think tank meeting on breast cancer: International expert panel white paper. 61
32450277 2020
10
The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. 61
31933123 2020
11
Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling. 61
31907974 2020
12
Long-Term Outcomes of Multiple-Wire Localizations for More Extensive Breast Cancer: Multiple-Wire Excision Does Not Increase Recurrence, Unplanned Imaging, or Biopsies. 61
31859233 2020
13
Adjuvant endocrine treatment for estrogen receptor (ER)-positive/ HER2-negative breast cancer. 61
32527118 2020
14
Potential Role of Convolutional Neural Network Based Algorithm in Patient Selection for DCIS Observation Trials Using a Mammogram Dataset. 61
31526687 2020
15
Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. 61
31925342 2020
16
A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ. 61
32147404 2020
17
Metastatic "Ductal Carcinoma In Situ-Like" Lobular Carcinoma in a Lymph Node: A Case Report and Review of the Literature. 61
31789065 2020
18
HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence. 61
32493703 2020
19
Adoption of SSO-ASTRO Margin Guidelines for Ductal Carcinoma in Situ: What Is the Impact on Use of Additional Surgery? 61
32500343 2020
20
Tumor-infiltrating lymphocytes in ductal carcinoma in situ- assessment using three different methodologies and correlation with Oncotype DX DCIS Score. 61
32557780 2020
21
LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target. 61
32522170 2020
22
Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis. 61
32529407 2020
23
Radioactive Seed Versus Wire-Guided Localization for Ductal Carcinoma in Situ of the Breast: Comparable Resection Margins. 61
32578065 2020
24
[Reducing the risk of ipsilateral breast tumor relapse: external beam accelerated partial breast irradiation vs. whole breast irradiation following breast-conserving surgery in patients with ductal carcinoma in situ and node-negative breast cancer : The multicentric randomised RAPID trial]. 61
32342118 2020
25
Intraductal Therapy in Breast Cancer: Current Status and Future Prospective. 61
32577880 2020
26
Membranous overexpression of S100A10 is associated with a high-grade cellular status of breast carcinoma. 61
31728728 2020
27
Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ. 61
32493410 2020
28
Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. 61
31897820 2020
29
Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? 61
31898097 2020
30
A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction. 61
32350679 2020
31
Interobserver Variability in Ductal Carcinoma In Situ of the Breast. 61
32566938 2020
32
Prediction of Upstaged Ductal Carcinoma In Situ Using Forced Labeling and Domain Adaptation. 61
31502960 2020
33
A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma In Situ. 61
31937618 2020
34
Analysis of active surveillance as a treatment modality in ductal carcinoma in situ. 61
31925857 2020
35
Characteristics of Microinvasive Ductal Carcinoma In Situ Versus Noninvasive and Invasive Breast Cancer. 61
32535256 2020
36
Is it ductal carcinoma in situ with microinvasion or "Ductogenesis"? The role of myoepithelial cell markers. 61
32447817 2020
37
Single-Institution Phase 1/2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial-Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer. 61
32084524 2020
38
Stromal Collagen Content in Breast Tumors Correlates With In Vivo Diffusion-Weighted Imaging: A Comparison of Multi b-Value DWI With Histologic Specimen From Benign and Malignant Breast Lesions. 61
31837076 2020
39
Screening Mammography Outcomes: Risk of Breast Cancer and Mortality by Comorbidity Score and Age. 61
31593591 2020
40
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer. 61
32103597 2020
41
The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort. 61
32311194 2020
42
Omics Integration Analyses Reveal the Early Evolution of Malignancy in Breast Cancer. 61
32512721 2020
43
Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience. 61
31218842 2020
44
Stem Cell Determinant SOX9 Promotes Lineage Plasticity and Progression in Basal-like Breast Cancer. 61
32521267 2020
45
Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis. 61
32522804 2020
46
A mouse SWATH-MS reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts. 61
32493768 2020
47
Evaluation of surgically excised breast tissue microstructure using wide-field optical coherence tomography. 61
31612563 2020
48
Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer. 61
32466799 2020
49
Risk factors for fat necrosis after stereotactic partial breast irradiation (S-PBI) for early stage breast cancer in a phase I clinical trial. 61
32464155 2020
50
The effect of an e-learning module on grading variation of (pre)malignant breast lesions. 61
32404951 2020

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

9 (show top 50) (show all 369)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149317650 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 6
2 COSM87900157 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 6
3 COSM87898709 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 6
4 COSM87899395 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 17:7673796-7673796 6
5 COSM87899661 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 6
6 COSM87906851 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 17:7673784-7673784 6
7 COSM87906185 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 6
8 COSM87990558 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 17:7673760-7673760 6
9 COSM87897711 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 6
10 COSM87943620 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 6
11 COSM87898578 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 6
12 COSM87915191 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 6
13 COSM87899842 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 6
14 COSM87898351 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 6
15 COSM87907089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 6
16 COSM89652676 SMARCA4 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 6
17 COSM91776956 PPP2R1A breast,NS,carcinoma in situ,ductal carcinoma in situ c.510C>A p.F170L 19:52212692-52212692 6
18 COSM87132272 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 6
19 COSM87132245 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 3:179234297-179234297 6
20 COSM87132454 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 3:179234297-179234297 6
21 COSM87132301 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 3:179218294-179218294 6
22 COSM87134467 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 3:179234296-179234296 6
23 COSM87132308 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 3:179218303-179218303 6
24 COSM87132330 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 3:179203765-179203765 6
25 COSM97107777 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 1:114716126-114716126 6
26 COSM97107326 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 1:114713909-114713909 6
27 COSM87645669 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 9:136496367-136496367 6
28 COSM101146280 MYCL breast,NS,carcinoma in situ,ductal carcinoma in situ c.659C>T p.T220M 1:39897898-39897898 6
29 COSM85396421 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 19:4097332-4097332 6
30 COSM87804005 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 6
31 COSM87804075 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 12:25245351-25245351 6
32 COSM87804055 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 12:25245350-25245350 6
33 COSM87804028 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 12:25245347-25245347 6
34 COSM88386447 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7:152273792-152273792 6
35 COSM88397801 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7:152235905-152235905 6
36 COSM112989732 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 11:533908-533908 6
37 COSM95516872 H3-3A breast,NS,carcinoma in situ,ductal carcinoma in situ c.218G>A p.R73Q 1:226065745-226065745 6
38 COSM88586406 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 17:39723967-39723967 6
39 COSM88585849 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.929C>T p.S310F 17:39711955-39711955 6
40 COSM87756352 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 6
41 COSM133536627 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 14:104780202-104780202 6
42 COSM133535772 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 14:104780214-104780214 6
43 COSM145165829 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 6
44 COSM143944147 breast,NS,carcinoma in situ,ductal carcinoma in situ c.265C>T p.R89W 17:7674221-7674221 6
45 COSM112254852 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 6
46 COSM148932677 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 6
47 COSM122733862 breast,NS,carcinoma in situ,ductal carcinoma in situ c.422G>A p.R141H 17:7673802-7673802 6
48 COSM144092525 breast,NS,carcinoma in situ,ductal carcinoma in situ c.110G>C p.R37P 17:7674944-7674944 6
49 COSM112253807 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 6
50 COSM91859716 breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 6

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TP53 PTGS2 MUC1 ESR1 ERBB2 EGFR
2
Show member pathways
13.73 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
3
Show member pathways
13.4 TP53 PTGS2 MUC1 ERBB2 EGFR EGF
4
Show member pathways
13.11 TP53 EGFR EGF CLDN7 CCND1 AKT1
5
Show member pathways
13.02 TP53 PTGS2 ERBB2 EGFR EGF CCND1
6
Show member pathways
13 TP53 PTGS2 EGFR CDKN2A CCND1 AKT1
7
Show member pathways
12.96 PTGS2 ERBB2 EGFR EGF CCND1 AKT1
8
Show member pathways
12.88 TP53 ERBB2 EGFR EGF CDKN2A CDH1
9 12.82 TP53 ERBB2 EGFR EGF AKT1
10
Show member pathways
12.78 TP53 ERBB2 EGFR EGF AKT1
11
Show member pathways
12.77 TP53 PTGS2 ESR1 ERBB2 CDH1 AKT1
12
Show member pathways
12.76 TP53 ESR1 CCND1 BRCA2 BRCA1
13
Show member pathways
12.74 PGR KRT14 ESR1 EGFR AKT1
14 12.72 TP53 PTGS2 ESR1 ERBB2 EGFR EGF
15
Show member pathways
12.68 TP53 ERBB2 EGFR EGF CCND1 AKT1
16 12.57 TP53 CDKN2A CCND1 BRCA2 BRCA1
17
Show member pathways
12.57 TP53 MUC1 EGFR EGF CDH1 AKT1
18 12.51 TP53 PTGS2 MIR17 ERBB2 EGFR CDKN2A
19 12.48 TP53 PTGS2 CDH1 CCND1 AKT1
20
Show member pathways
12.46 PTGS2 ESR1 CD44 BRCA1 AKT1
21 12.45 TP53 EGFR CD44 AKT1
22
Show member pathways
12.44 TP53 MIR17 CDKN2A CCND1 BRCA1
23 12.42 TP53 CDKN2A CDH1 CCND1
24 12.4 TP53 CDKN2A CCND1 AKT1
25
Show member pathways
12.38 MUC1 ERBB2 EGFR EGF CDH1 AKT1
26
Show member pathways
12.38 PTGS2 ESR1 ERBB2 EGFR EGF CCND1
27
Show member pathways
12.37 ERBB2 EGFR EGF AKT1
28
Show member pathways
12.36 TP53 ERBB2 EGFR EGF CCND1 AKT1
29 12.35 TP53 ESR1 ERBB2 EGFR CD44 CCND1
30
Show member pathways
12.31 TP53 CCND1 BRCA1 AKT1
31
Show member pathways
12.3 TP53 ERBB2 EGFR CCND1 AKT1
32
Show member pathways
12.29 PGR ESR1 CDKN2A CCND1 BRCA1
33
Show member pathways
12.29 TP53 ESR1 ERBB2 EGFR EGF CDKN2A
34 12.25 ERBB2 EGFR EGF AKT1
35 12.22 TP53 CDKN2A CCND1 AKT1
36
Show member pathways
12.2 ERBB2 EGFR EGF AKT1
37 12.19 TP53 PTGS2 EGFR EGF CDH1 CCND1
38
Show member pathways
12.15 EGFR EGF CCND1 AKT1
39
Show member pathways
12.13 ERBB2 EGFR EGF CCND1 AKT1
40
Show member pathways
12.1 TP53 ERBB2 EGFR AKT1
41 12.08 TP53 ESR1 CCND1 AKT1
42 12.07 TP53 PTGS2 EGFR CCND1
43
Show member pathways
12.07 TP53 PGR ESR1 ERBB2 EGFR EGF
44 12.06 TP53 ERBB2 CDKN2A CCND1 AKT1
45 12.05 TP53 PTGS2 MUC1 CCND1 AKT1
46 12.05 TP53 EGFR EGF CDKN2A CCND1 AKT1
47 12.02 ERBB2 EGFR EGF AKT1
48 12.01 EGFR EGF CDH1 AKT1
49
Show member pathways
12.01 PGR ESR1 ERBB2 EGFR EGF
50 12 TP53 ESR1 EGFR CYP19A1 CDH1 CCND1

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.06 TP53 PTGS2 PGR MUC1 KRT5 ESR1
2 cytoplasm GO:0005737 9.83 TP53 PTGS2 PGR MUC1 KRT5 KRT14
3 basolateral plasma membrane GO:0016323 9.56 ERBB2 EGFR CLDN7 CD44
4 protein-containing complex GO:0032991 9.17 TP53 PTGS2 ESR1 EGFR BRCA2 BRCA1

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 TP53 PGR ESR1 EGFR CDKN2A BRCA1
2 cellular response to DNA damage stimulus GO:0006974 10.1 TP53 CCND1 BRCA2 BRCA1 AKT1
3 negative regulation of apoptotic process GO:0043066 10.05 TP53 PTGS2 EGFR CLDN7 CD44 AKT1
4 negative regulation of gene expression GO:0010629 9.99 TP53 PGR MIR17 ESR1 AKT1
5 positive regulation of gene expression GO:0010628 9.99 TP53 ERBB2 EGF CDKN2A BRCA1 AKT1
6 regulation of cell proliferation GO:0042127 9.98 TP53 PTGS2 EGFR BRCA1
7 cytokine-mediated signaling pathway GO:0019221 9.97 TP53 PTGS2 MUC1 CCND1 AKT1
8 positive regulation of protein phosphorylation GO:0001934 9.95 ERBB2 EGFR CCND1 AKT1
9 positive regulation of protein kinase B signaling GO:0051897 9.95 ESR1 ERBB2 EGFR EGF
10 positive regulation of cell proliferation GO:0008284 9.91 PTGS2 ERBB2 EGFR EGF CLDN7 CCND1
11 cellular response to hypoxia GO:0071456 9.9 TP53 PTGS2 MIR17 AKT1
12 response to oxidative stress GO:0006979 9.88 TP53 PTGS2 EGFR AKT1
13 cellular response to mechanical stimulus GO:0071260 9.87 PTGS2 EGFR AKT1
14 positive regulation of kinase activity GO:0033674 9.86 ERBB2 EGFR CD44
15 cellular response to growth factor stimulus GO:0071363 9.86 ERBB2 EGFR AKT1
16 double-strand break repair GO:0006302 9.85 TP53 BRCA2 BRCA1
17 positive regulation of epithelial cell proliferation GO:0050679 9.85 ERBB2 EGFR CCND1
18 response to estrogen GO:0043627 9.84 ESR1 CCND1 BRCA1
19 positive regulation of MAP kinase activity GO:0043406 9.84 ERBB2 EGFR EGF
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 PTGS2 EGFR AKT1
21 positive regulation of fibroblast proliferation GO:0048146 9.82 MIR17 ESR1 EGFR
22 epidermal growth factor receptor signaling pathway GO:0007173 9.81 EGFR EGF AKT1
23 response to organic substance GO:0010033 9.8 PTGS2 CDH1 CCND1 AKT1
24 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.79 EGFR CCND1 AKT1
25 cellular response to epidermal growth factor stimulus GO:0071364 9.79 ERBB2 EGFR AKT1
26 negative regulation of Notch signaling pathway GO:0045746 9.78 EGFR EGF AKT1
27 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 PTGS2 EGFR CD44 AKT1
28 positive regulation of vasoconstriction GO:0045907 9.73 PTGS2 EGFR AKT1
29 regulation of cell motility GO:2000145 9.72 ERBB2 EGFR EGF
30 response to estradiol GO:0032355 9.72 PTGS2 ESR1 EGFR CYP19A1 CCND1
31 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.71 EGFR CCND1 AKT1
32 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.71 PTGS2 MIR17 CD44 AKT1
33 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.7 TP53 EGFR
34 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.7 TP53 ESR1
35 ERBB2 signaling pathway GO:0038128 9.7 ERBB2 EGFR EGF
36 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.69 TP53 ESR1
37 mitotic G1 DNA damage checkpoint GO:0031571 9.67 TP53 CCND1
38 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.65 TP53 MUC1
39 cellular response to indole-3-methanol GO:0071681 9.63 CDH1 BRCA1
40 chordate embryonic development GO:0043009 9.63 BRCA2 BRCA1
41 response to X-ray GO:0010165 9.63 TP53 CCND1 BRCA2
42 negative regulation of immature T cell proliferation in thymus GO:0033088 9.62 ERBB2 CDKN2A
43 mammary gland alveolus development GO:0060749 9.61 ESR1 EGF CCND1
44 positive regulation of transcription, DNA-templated GO:0045893 9.61 TP53 ESR1 EGFR EGF CDKN2A CDH1
45 negative regulation of ERBB signaling pathway GO:1901185 9.43 ERBB2 EGFR EGF
46 response to UV-A GO:0070141 9.33 EGFR CCND1 AKT1
47 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 TP53 MUC1 BRCA2 BRCA1

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 TP53 PTGS2 PGR MUC1 KRT5 KRT14
2 protein kinase binding GO:0019901 9.73 TP53 ESR1 EGFR CDKN2A CCND1 AKT1
3 identical protein binding GO:0042802 9.65 TP53 PGR ESR1 ERBB2 EGFR CLDN7
4 nitric-oxide synthase regulator activity GO:0030235 9.33 ESR1 EGFR AKT1
5 enzyme binding GO:0019899 9.23 TP53 PTGS2 PGR ESR1 EGFR CCND1

Sources for Ductal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....